Aptorum Group Limited

Equities

APM

KYG6096M1226

Pharmaceuticals

Real-time Estimate Cboe BZX 12:58:38 2024-04-18 pm EDT 5-day change 1st Jan Change
5.55 USD -23.45% Intraday chart for Aptorum Group Limited -35.31% +127.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Top Midday Gainers MT
YOOV Group Holding Limited entered into a entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited for $250 million in a reverse merger transaction. CI
Top Premarket Decliners MT
Aptorum Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Aptorum Group Limited Announces Chief Executive Changes CI
Aptorum Group Limited Announces Management Changes CI
Aptorum Group Limited announced that it has received $3 million in funding from Jurchen Investment Corporation CI
Top Premarket Decliners MT
Aptorum Group Obtains Nasdaq Authorization to Transfer Listing to Nasdaq Capital Market MT
Top Premarket Gainers MT
Aptorum Group Limited Announces Resignation of Thomas Lee as Head of Research and Development CI
Aptorum Group Limited announced that it has received $3 million in funding CI
Aptorum Group Limited Provides Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma CI
Biopharmaceutical Group Aptorum to Delist from Euronext Paris MT
Top Premarket Decliners MT
Top Midday Decliners MT
Looming Economic Data Prompt Quiet Premarket Action for US Equity Futures MT
Top Premarket Decliners MT
Aptorum Group Gets Non-Compliance Notice From Nasdaq -- Shares Slump in Premarket MT
Aptorum Group Gets Non-Compliance Notice From Nasdaq MT
Top Premarket Gainers MT
Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Aptorum, URF Holding Group to Combine in Reverse Takeover MT
URF Holding Group Limited entered into a non-binding Letter of Intent and Term Sheet to acquire Aptorum Group Limited for $40 million in a reverse merger transaction. CI
Aptorum Group Completes US FDA Meetings for ALS-4, SACT-1 MT
Chart Aptorum Group Limited
More charts
Aptorum Group Limited is United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's business segments include Therapeutics and Non-Therapeutics. Therapeutics segment is engaged in developing various drug molecules and certain technologies for treatment of human disease conditions. Two of the Company’s lead projects, ALS-4 and SACT-1, target infectious disease and cancer, including orphan oncology indications. Non-Therapeutics segment encompasses three businesses: diagnostics projects including PathsDx Test, natural supplements including NativusWell, and AML Clinic. PathsDx Test is a novel molecular-based rapid pathogen identification and detection diagnostics technology, which is under co-development with A*STAR.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. APM Stock
  4. News Aptorum Group Limited
  5. Sector Update: Health Care Stocks Posting Moderate Advance